Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-FR Version v2-FR
Language French French
Date Updated 2018-08-30 2017-11-30
Drug Identification Number 02436027 02436027
Brand name HOLKIRA PAK HOLKIRA PAK
Common or Proper name HOLKIRA PAK 12.5/75/50/250MG TABS, 28DAY HOLKIRA PAK 12.5/75/50/250MG TABS, 28DAY
Company Name ABBVIE CORPORATION ABBVIE CORPORATION
Ingredients RITONAVIR Ombitasvir Dasabuvir Paritaprevir RITONAVIR Ombitasvir Dasabuvir Paritaprevir
Strength(s) 50MG 12.5MG 250MG 75MG 50MG 12.5MG 250MG 75MG
Dosage form(s) KIT TABLET KIT TABLET
Route of administration ORAL ORAL
Packaging size 4 inner cartons x 7blisters 4 inner cartons x 7blisters
ATC code J05AX J05AX
ATC description DIRECT ACTING ANTIVIRALS DIRECT ACTING ANTIVIRALS
Reason for discontinuation Business reasons Business reasons
Anticipated discontinuation date 2018-08-15 2018-08-15
Actual discontinuation date 2018-08-15
Remaining supply date 2018-08-15 2018-08-15
Discontinuation status Discontinued To be discontinued
Discontinuation decision reversal no no
Tier 3 Status No No
Information on remaining supply
Company comments This decision follows Health Canada’s recent approval of MAVIRET Tablets, AbbVie’s new pan-genotypic antiviral for the treatment of adults with chronic hepatitis C virus (HCV), which will replace HOLKIRA PAK, TECHNIVIE and MODERIBA on the Canadian market. This decision follows Health Canada’s recent approval of MAVIRET Tablets, AbbVie’s new pan-genotypic antiviral for the treatment of adults with chronic hepatitis C virus (HCV), which will replace HOLKIRA PAK, TECHNIVIE and MODERIBA on the Canadian market.
Health Canada comments